Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Cladribine selectively targets B and T cells, which are key contributors to autoimmune diseases such as NMOSD and g